1. AZD8186 study 1: Phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. (December 2016) Authors: Lillian, S.; De Bono, J.; Higano, C.; Shapiro, G.; Brugger, W.; Mitchell, P.; Colebrook, S.; Klinowska, T.; Barry, S.; Dean, E.; Martin-Mills, J.; Wisinski, K.; Moorthy, G.; Mills, J.; Cruzalegui, F.; Tolaney, S.; Lang, J.; Jose De Miquel Luken, M.; Kunar, R.; Chatta, G. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗